Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for ELVN

Stock Name	Enliven Therapeutics Inc.
Ticker	ELVN(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US29337E1029

Show aggregate ELVN holdings

News associated with ELVN

Brokerages Set Enliven Therapeutics, Inc. (NASDAQ:ELVN) PT at $41.20: Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) has earned a consensus recommendation of “Buy” from the five ratings firms that are currently covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have updated their coverage on the stock in the […] - 2025-08-08 02:42:46
Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $281,500.00 in Stock: Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CEO Samuel Kintz sold 12,500 shares of the company’s stock in a transaction dated Thursday, July 17th. The stock was sold at an average price of $22.52, for a total transaction of $281,500.00. Following the transaction, the chief executive officer owned 940,392 shares in the company, valued […] - 2025-07-22 07:14:55
Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 1,000 Shares: Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CFO Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock in a transaction dated Thursday, July 10th. The shares were sold at an average price of $22.66, for a total transaction of $22,660.00. Following the transaction, the chief financial officer directly owned 23,000 shares of the company’s […] - 2025-07-15 06:21:06
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Recommendation of “Buy” from Brokerages: Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) have received an average recommendation of “Buy” from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued a […] - 2025-07-11 05:23:02
Enliven Therapeutics (NASDAQ:ELVN) Trading 7.9% Higher Following Analyst Upgrade: Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report)’s stock price was up 7.9% on Wednesday after HC Wainwright raised their price target on the stock from $40.00 to $48.00. HC Wainwright currently has a buy rating on the stock. Enliven Therapeutics traded as high as $20.74 and last traded at $21.20. Approximately 171,529 shares traded […] - 2025-07-04 02:24:46
Exchange Traded Concepts LLC Reduces Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN): Exchange Traded Concepts LLC decreased its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 19.1% in the 1st quarter, Holdings Channel.com reports. The firm owned 6,055 shares of the company’s stock after selling 1,428 shares during the period. Exchange Traded Concepts LLC’s holdings in Enliven Therapeutics were worth $119,000 as of its most […] - 2025-06-24 04:38:52
Rhumbline Advisers Increases Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN): Rhumbline Advisers raised its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 4.9% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 52,502 shares of the company’s stock after acquiring an additional 2,466 shares during the period. Rhumbline Advisers’ holdings in Enliven Therapeutics were worth $1,033,000 […] - 2025-06-20 04:22:47
Robert W. Baird Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock: Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) had its target price lifted by equities research analysts at Robert W. Baird from $40.00 to $52.00 in a report issued on Monday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird’s price target indicates a potential upside of 138.53% from the stock’s […] - 2025-06-18 03:08:46
Enliven Therapeutics (NASDAQ:ELVN) Coverage Initiated at The Goldman Sachs Group: Investment analysts at The Goldman Sachs Group assumed coverage on shares of Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) in a report released on Monday, MarketBeat Ratings reports. The firm set a “buy” rating and a $37.00 price target on the stock. The Goldman Sachs Group’s target price suggests a potential upside of 69.72% from […] - 2025-06-18 03:08:45
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up Following Analyst Upgrade: Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report)’s stock price gapped up prior to trading on Monday after Robert W. Baird raised their price target on the stock from $40.00 to $52.00. The stock had previously closed at $21.91, but opened at $23.38. Robert W. Baird currently has an outperform rating on the stock. Enliven […] - 2025-06-17 02:08:49
Two Sigma Investments LP Decreases Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN): Two Sigma Investments LP lowered its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 33.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 14,620 shares of the company’s stock after selling 7,460 shares during the quarter. Two Sigma Investments LP’s holdings in Enliven Therapeutics were worth $329,000 as of its […] - 2025-06-11 04:30:51
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.: MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 3.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,036 shares of the company’s stock after purchasing an additional 718 shares during the […] - 2025-05-30 04:55:02
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Recommendation of “Buy” by Brokerages: Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) have been assigned an average rating of “Buy” from the five analysts that are covering the company, MarketBeat reports. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month […] - 2025-05-27 05:26:58
Voya Investment Management LLC Decreases Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN): Voya Investment Management LLC trimmed its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 8.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,702 shares of the company’s stock after selling 945 shares during the quarter. Voya […] - 2025-05-13 05:22:51
Marshall Wace LLP Has $931,000 Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN): Marshall Wace LLP cut its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 70.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 41,382 shares of the company’s stock after selling 96,624 shares during the quarter. Marshall Wace LLP’s holdings in Enliven Therapeutics were worth $931,000 at the end […] - 2025-05-01 04:50:53
ExodusPoint Capital Management LP Acquires New Shares in Enliven Therapeutics, Inc. (NASDAQ:ELVN): ExodusPoint Capital Management LP bought a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 8,900 shares of the company’s stock, valued at approximately $200,000. Other hedge funds have also added to or reduced […] - 2025-04-15 04:39:25
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by Fmr LLC: Fmr LLC grew its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 3.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,495,871 shares of the company’s stock after acquiring an additional 199,692 shares during the quarter. Fmr LLC owned about 0.13% […] - 2025-04-14 05:48:47
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock Holdings Lowered by Corebridge Financial Inc.: Corebridge Financial Inc. cut its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 7.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,500 shares of the company’s stock after selling 1,321 shares during the quarter. […] - 2025-04-10 04:49:04
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 4.9% Following Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report)’s share price traded down 4.9% during mid-day trading on Tuesday following insider selling activity. The stock traded as low as $18.61 and last traded at $18.73. 40,658 shares were traded during mid-day trading, a decline of 85% from the average session volume of 275,231 shares. The stock […] - 2025-04-03 02:44:44
Tuesday's ETF Movers: BLOK, IHE: In trading on Tuesday, the Amplify Transformational Data Sharing ETF is outperforming other ETFs, up about 1.8% on the day. Components of that ETF showing particular strength include shares of Core Scientific, up about 8.1% and shares of Applied Digital, up about 6.6% on the da - 2025-04-01 13:04:57
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, HC Wainwright Analyst Says: Enliven Therapeutics (NASDAQ:ELVN – Free Report) had its price objective lifted by HC Wainwright from $37.00 to $39.00 in a research report sent to investors on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. Separately, BTIG Research began coverage on Enliven Therapeutics in a report on Friday, December 13th. They set […] - 2025-03-24 04:13:03

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc ELVN holdings

Date	Number of ELVN Shares Held	Base Market Value of ELVN Shares	Local Market Value of ELVN Shares	Change in ELVN Shares Held	Change in ELVN Base Value	Current Price per ELVN Share Held	Previous Price per ELVN Share Held
2026-01-15 (Thursday)	67,409	USD 1,696,685	USD 1,696,685	10,348	USD 210,246	USD 25.17	USD 26.05
2026-01-14 (Wednesday)	57,061	USD 1,486,439	USD 1,486,439	199	USD 22,242	USD 26.05	USD 25.75
2026-01-13 (Tuesday)	56,862	USD 1,464,197	USD 1,464,197	0	USD 40,941	USD 25.75	USD 25.03
2026-01-12 (Monday)	56,862	USD 1,423,256	USD 1,423,256	0	USD -55,156	USD 25.03	USD 26
2026-01-09 (Friday)	56,862	USD 1,478,412	USD 1,478,412	199	USD 160,997	USD 26	USD 23.25
2026-01-08 (Thursday)	56,663	USD 1,317,415	USD 1,317,415	0	USD 440,838	USD 23.25	USD 15.47
2026-01-07 (Wednesday)	56,663	USD 876,577	USD 876,577	0	USD 18,699	USD 15.47	USD 15.14
2026-01-06 (Tuesday)	56,663	USD 857,878	USD 857,878	0	USD -3,966	USD 15.14	USD 15.21
2026-01-05 (Monday)	56,663	USD 861,844	USD 861,844	0	USD -18,699	USD 15.21	USD 15.54
2026-01-02 (Friday)	56,663	USD 880,543	USD 880,543	0	USD 7,933	USD 15.54	USD 15.4
2025-12-31 (Wednesday)	56,663	USD 872,610	USD 872,610	0	USD -8,500	USD 15.4	USD 15.55

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ELVN by Blackrock for IE00B3VWM098

Show aggregate share trades of ELVN

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2026-01-15 BUY 10,348 26.190 24.290 24.480 USD 253,319 20.95
2026-01-14 BUY 199 27.395 24.890 25.140 USD 5,003 20.92
2026-01-09 BUY 199 29.980 23.272 23.943 USD 4,765 20.87
2025-12-23 SELL -199 17.880 16.475 16.616 USD -3,306 21.08 Profit of 889 on sale
2025-12-03 SELL -995 21.020 20.220 20.300 USD -20,198 21.24 Profit of 935 on sale
2025-12-02 BUY 398 20.700 19.920 19.998 USD 7,959 21.24
2025-11-25 SELL -597 22.450 21.550 21.640 USD -12,919 21.24 Loss of -238 on sale
2025-11-24 SELL -597 22.790 21.636 21.751 USD -12,986 21.24 Loss of -306 on sale
2025-11-17 SELL -2,200 22.270 21.280 21.379 USD -47,034 21.22 Loss of -345 on sale
2025-11-12 SELL -200 20.620 19.630 19.729 USD -3,946 21.23 Profit of 300 on sale
2025-11-06 SELL -200 18.560 17.810 17.885 USD -3,577 21.28 Profit of 680 on sale
2025-11-05 SELL -2,000 19.000 17.770 17.893 USD -35,786 21.30 Profit of 6,809 on sale
2025-11-04 SELL -400 20.230 18.630 18.790 USD -7,516 21.31 Profit of 1,008 on sale
2025-11-03 SELL -400 23.310 18.330 18.828 USD -7,531 21.32 Profit of 995 on sale
2025-10-28 BUY 600 21.550 21.680 21.667 USD 13,000 21.28
2025-10-24 SELL -200 20.610 20.820 20.799 USD -4,160 21.29 Profit of 97 on sale
2025-10-15 BUY 1,200 21.730 21.750 21.748 USD 26,098 21.28
2025-10-03 BUY 5,543 19.610 20.193 20.135 USD 111,607 21.29
2025-10-02 BUY 182 19.920 20.090 20.073 USD 3,653 21.30
2025-09-30 BUY 364 20.470 20.900 20.857 USD 7,592 21.31
2025-08-21 SELL -163 19.840 20.275 20.231 USD -3,298 21.37 Profit of 185 on sale
2025-07-31 BUY 489 18.810 19.440 19.377 USD 9,475 21.39
2025-06-30 SELL -326 20.060 21.210 21.095 USD -6,877 21.42 Profit of 107 on sale
2025-06-25 SELL -163 21.500 21.660 21.644 USD -3,528 21.43 Loss of -35 on sale
2025-06-20 SELL -326 21.300 22.070 21.993 USD -7,170 21.44 Loss of -180 on sale
2025-05-30 BUY 5,672 17.770 18.250 18.202 USD 103,242 21.50
2025-05-23 BUY 144 16.400 16.950 16.895 USD 2,433 21.70
2025-05-19 SELL -144 16.850 17.280 17.237 USD -2,482 21.87 Profit of 667 on sale
2025-05-15 SELL -432 17.820 20.000 19.782 USD -8,546 21.95 Profit of 935 on sale
2025-05-12 SELL -144 19.010 19.850 19.766 USD -2,846 22.01 Profit of 323 on sale
2025-05-09 SELL -144 18.420 19.670 19.545 USD -2,814 22.04 Profit of 360 on sale
2025-04-30 SELL -144 18.940 19.219 19.191 USD -2,764 22.22 Profit of 436 on sale
2025-04-24 SELL -288 18.300 18.570 18.543 USD -5,340 22.37 Profit of 1,101 on sale
2025-04-17 SELL -144 16.530 16.854 16.822 USD -2,422 22.65 Profit of 839 on sale
2025-04-15 SELL -432 17.050 18.140 18.031 USD -7,789 22.78 Profit of 2,053 on sale
2025-04-14 SELL -432 17.190 17.380 17.361 USD -7,500 22.85 Profit of 2,369 on sale
2025-04-09 SELL -576 16.520 17.190 17.123 USD -9,863 23.08 Profit of 3,431 on sale
2025-04-07 SELL -1,008 17.870 19.690 19.508 USD -19,664 23.22 Profit of 3,746 on sale
2025-04-04 SELL -1,450 18.690 20.040 19.905 USD -28,862 23.28 Profit of 4,890 on sale
2025-03-31 BUY 145 19.680 21.160 21.012 USD 3,047 23.42
2025-03-19 SELL -290 20.890 21.180 21.151 USD -6,134 23.65 Profit of 726 on sale
2025-03-14 SELL -870 20.740 22.210 22.063 USD -19,195 23.78 Profit of 1,492 on sale
2025-03-13 SELL -290 20.290 21.120 21.037 USD -6,101 23.83 Profit of 809 on sale
2025-03-12 SELL -4,930 21.020 21.155 21.142 USD -104,228 23.87 Profit of 13,447 on sale
2025-03-07 SELL -290 21.000 22.290 22.161 USD -6,427 24.02 Profit of 538 on sale
2025-03-06 SELL -435 21.460 22.360 22.270 USD -9,687 24.05 Profit of 776 on sale
2025-03-03 SELL -145 19.620 21.238 21.076 USD -3,056 24.24 Profit of 458 on sale
2025-02-28 SELL -870 20.830 21.035 21.014 USD -18,283 24.29 Profit of 2,853 on sale
2025-02-26 SELL -145 20.280 20.750 20.703 USD -3,002 24.43 Profit of 541 on sale
2025-02-25 SELL -435 20.130 21.530 21.390 USD -9,305 24.51 Profit of 1,356 on sale
2025-02-18 BUY 725 21.820 22.355 22.301 USD 16,169 24.77
2025-02-13 BUY 145 21.500 22.910 22.769 USD 3,302 24.96
2025-02-12 BUY 145 22.050 22.080 22.077 USD 3,201 25.02
2025-02-11 BUY 435 21.410 21.820 21.779 USD 9,474 25.10
2025-02-06 BUY 1,305 22.470 23.180 23.109 USD 30,157 25.30
2025-01-27 BUY 145 21.290 22.280 22.181 USD 3,216 26.10
2024-12-30 BUY 725 22.390 22.775 22.736 USD 16,484 26.53
2024-12-06 BUY 580 25.420 25.960 25.906 USD 15,025 26.73
2024-12-05 BUY 145 23.250 24.145 24.056 USD 3,488 26.85
2024-12-04 BUY 725 23.710 23.980 23.953 USD 17,366 26.96
2024-11-29 BUY 725 24.380 25.630 25.505 USD 18,491 27.30
2024-11-27 BUY 580 25.410 25.670 25.644 USD 14,874 27.46
2024-11-26 BUY 145 24.350 25.070 24.998 USD 3,625 27.61
2024-11-25 BUY 4,493 24.880 25.640 25.564 USD 114,859 27.74
2024-11-21 BUY 650 25.410 25.760 25.725 USD 16,721 28.03
2024-11-20 BUY 390 25.430 26.480 26.375 USD 10,286 28.17
2024-11-18 BUY 1,560 24.900 24.925 24.922 USD 38,879 28.50
2024-11-12 BUY 1,040 27.170 28.220 28.115 USD 29,240 28.59
2024-11-08 BUY 650 28.960 29.400 29.356 USD 19,081 28.56
2024-11-07 BUY 1,950 29.000 29.785 29.706 USD 57,928 28.53
2024-11-06 BUY 260 29.550 29.650 29.640 USD 7,706 28.44
2024-10-31 BUY 130 27.850 29.090 28.966 USD 3,766 28.77
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2026-01-15	BUY	10,348	26.190	24.290	24.480	USD 253,319	20.95
2026-01-14	BUY	199	27.395	24.890	25.140	USD 5,003	20.92
2026-01-09	BUY	199	29.980	23.272	23.943	USD 4,765	20.87
2025-12-23	SELL	-199	17.880	16.475	16.616	USD -3,306	21.08 Profit of 889 on sale
2025-12-03	SELL	-995	21.020	20.220	20.300	USD -20,198	21.24 Profit of 935 on sale
2025-12-02	BUY	398	20.700	19.920	19.998	USD 7,959	21.24
2025-11-25	SELL	-597	22.450	21.550	21.640	USD -12,919	21.24 Loss of -238 on sale
2025-11-24	SELL	-597	22.790	21.636	21.751	USD -12,986	21.24 Loss of -306 on sale
2025-11-17	SELL	-2,200	22.270	21.280	21.379	USD -47,034	21.22 Loss of -345 on sale
2025-11-12	SELL	-200	20.620	19.630	19.729	USD -3,946	21.23 Profit of 300 on sale
2025-11-06	SELL	-200	18.560	17.810	17.885	USD -3,577	21.28 Profit of 680 on sale
2025-11-05	SELL	-2,000	19.000	17.770	17.893	USD -35,786	21.30 Profit of 6,809 on sale
2025-11-04	SELL	-400	20.230	18.630	18.790	USD -7,516	21.31 Profit of 1,008 on sale
2025-11-03	SELL	-400	23.310	18.330	18.828	USD -7,531	21.32 Profit of 995 on sale
2025-10-28	BUY	600	21.550	21.680	21.667	USD 13,000	21.28
2025-10-24	SELL	-200	20.610	20.820	20.799	USD -4,160	21.29 Profit of 97 on sale
2025-10-15	BUY	1,200	21.730	21.750	21.748	USD 26,098	21.28
2025-10-03	BUY	5,543	19.610	20.193	20.135	USD 111,607	21.29
2025-10-02	BUY	182	19.920	20.090	20.073	USD 3,653	21.30
2025-09-30	BUY	364	20.470	20.900	20.857	USD 7,592	21.31
2025-08-21	SELL	-163	19.840	20.275	20.231	USD -3,298	21.37 Profit of 185 on sale
2025-07-31	BUY	489	18.810	19.440	19.377	USD 9,475	21.39
2025-06-30	SELL	-326	20.060	21.210	21.095	USD -6,877	21.42 Profit of 107 on sale
2025-06-25	SELL	-163	21.500	21.660	21.644	USD -3,528	21.43 Loss of -35 on sale
2025-06-20	SELL	-326	21.300	22.070	21.993	USD -7,170	21.44 Loss of -180 on sale
2025-05-30	BUY	5,672	17.770	18.250	18.202	USD 103,242	21.50
2025-05-23	BUY	144	16.400	16.950	16.895	USD 2,433	21.70
2025-05-19	SELL	-144	16.850	17.280	17.237	USD -2,482	21.87 Profit of 667 on sale
2025-05-15	SELL	-432	17.820	20.000	19.782	USD -8,546	21.95 Profit of 935 on sale
2025-05-12	SELL	-144	19.010	19.850	19.766	USD -2,846	22.01 Profit of 323 on sale
2025-05-09	SELL	-144	18.420	19.670	19.545	USD -2,814	22.04 Profit of 360 on sale
2025-04-30	SELL	-144	18.940	19.219	19.191	USD -2,764	22.22 Profit of 436 on sale
2025-04-24	SELL	-288	18.300	18.570	18.543	USD -5,340	22.37 Profit of 1,101 on sale
2025-04-17	SELL	-144	16.530	16.854	16.822	USD -2,422	22.65 Profit of 839 on sale
2025-04-15	SELL	-432	17.050	18.140	18.031	USD -7,789	22.78 Profit of 2,053 on sale
2025-04-14	SELL	-432	17.190	17.380	17.361	USD -7,500	22.85 Profit of 2,369 on sale
2025-04-09	SELL	-576	16.520	17.190	17.123	USD -9,863	23.08 Profit of 3,431 on sale
2025-04-07	SELL	-1,008	17.870	19.690	19.508	USD -19,664	23.22 Profit of 3,746 on sale
2025-04-04	SELL	-1,450	18.690	20.040	19.905	USD -28,862	23.28 Profit of 4,890 on sale
2025-03-31	BUY	145	19.680	21.160	21.012	USD 3,047	23.42
2025-03-19	SELL	-290	20.890	21.180	21.151	USD -6,134	23.65 Profit of 726 on sale
2025-03-14	SELL	-870	20.740	22.210	22.063	USD -19,195	23.78 Profit of 1,492 on sale
2025-03-13	SELL	-290	20.290	21.120	21.037	USD -6,101	23.83 Profit of 809 on sale
2025-03-12	SELL	-4,930	21.020	21.155	21.142	USD -104,228	23.87 Profit of 13,447 on sale
2025-03-07	SELL	-290	21.000	22.290	22.161	USD -6,427	24.02 Profit of 538 on sale
2025-03-06	SELL	-435	21.460	22.360	22.270	USD -9,687	24.05 Profit of 776 on sale
2025-03-03	SELL	-145	19.620	21.238	21.076	USD -3,056	24.24 Profit of 458 on sale
2025-02-28	SELL	-870	20.830	21.035	21.014	USD -18,283	24.29 Profit of 2,853 on sale
2025-02-26	SELL	-145	20.280	20.750	20.703	USD -3,002	24.43 Profit of 541 on sale
2025-02-25	SELL	-435	20.130	21.530	21.390	USD -9,305	24.51 Profit of 1,356 on sale
2025-02-18	BUY	725	21.820	22.355	22.301	USD 16,169	24.77
2025-02-13	BUY	145	21.500	22.910	22.769	USD 3,302	24.96
2025-02-12	BUY	145	22.050	22.080	22.077	USD 3,201	25.02
2025-02-11	BUY	435	21.410	21.820	21.779	USD 9,474	25.10
2025-02-06	BUY	1,305	22.470	23.180	23.109	USD 30,157	25.30
2025-01-27	BUY	145	21.290	22.280	22.181	USD 3,216	26.10
2024-12-30	BUY	725	22.390	22.775	22.736	USD 16,484	26.53
2024-12-06	BUY	580	25.420	25.960	25.906	USD 15,025	26.73
2024-12-05	BUY	145	23.250	24.145	24.056	USD 3,488	26.85
2024-12-04	BUY	725	23.710	23.980	23.953	USD 17,366	26.96
2024-11-29	BUY	725	24.380	25.630	25.505	USD 18,491	27.30
2024-11-27	BUY	580	25.410	25.670	25.644	USD 14,874	27.46
2024-11-26	BUY	145	24.350	25.070	24.998	USD 3,625	27.61
2024-11-25	BUY	4,493	24.880	25.640	25.564	USD 114,859	27.74
2024-11-21	BUY	650	25.410	25.760	25.725	USD 16,721	28.03
2024-11-20	BUY	390	25.430	26.480	26.375	USD 10,286	28.17
2024-11-18	BUY	1,560	24.900	24.925	24.922	USD 38,879	28.50
2024-11-12	BUY	1,040	27.170	28.220	28.115	USD 29,240	28.59
2024-11-08	BUY	650	28.960	29.400	29.356	USD 19,081	28.56
2024-11-07	BUY	1,950	29.000	29.785	29.706	USD 57,928	28.53
2024-11-06	BUY	260	29.550	29.650	29.640	USD 7,706	28.44
2024-10-31	BUY	130	27.850	29.090	28.966	USD 3,766	28.77

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ELVN

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	255,512	2,440	367,300	69.6%
2025-09-18	205,742	0	372,476	55.2%
2025-09-17	162,926	1,997	258,660	63.0%
2025-09-16	210,614	0	354,409	59.4%
2025-09-15	158,968	15	285,258	55.7%
2025-09-12	150,977	0	331,828	45.5%
2025-09-11	96,060	0	385,686	24.9%
2025-09-10	47,949	6	151,232	31.7%
2025-09-09	131,883	0	239,214	55.1%
2025-09-08	196,306	8,811	347,785	56.4%
2025-09-05	63,256	0	131,309	48.2%
2025-09-04	78,435	0	146,468	53.6%
2025-09-03	105,005	0	189,634	55.4%
2025-09-02	92,210	308	154,107	59.8%
2025-08-29	152,705	246	324,867	47.0%
2025-08-28	113,372	0	320,884	35.3%
2025-08-27	114,853	2,880	257,350	44.6%
2025-08-26	36,937	0	145,789	25.3%
2025-08-25	150,668	0	277,238	54.3%
2025-08-22	164,536	0	493,351	33.4%
2025-08-21	208,223	1,982	440,282	47.3%
2025-08-20	69,564	1,006	132,987	52.3%
2025-08-19	42,058	3,410	78,032	53.9%
2025-08-18	52,776	3,411	113,030	46.7%
2025-08-15	49,843	607	137,044	36.4%
2025-08-14	60,767	0	121,823	49.9%
2025-08-13	77,834	0	145,516	53.5%
2025-08-12	76,411	0	165,024	46.3%
2025-08-11	49,374	0	80,191	61.6%
2025-08-08	148,399	100	336,540	44.1%
2025-08-07	75,044	2,200	122,751	61.1%
2025-08-06	123,117	20	222,055	55.4%
2025-08-05	103,501	0	245,375	42.2%
2025-08-04	36,934	0	99,774	37.0%
2025-08-01	100,865	0	290,379	34.7%
2025-07-31	72,665	0	189,293	38.4%
2025-07-30	83,029	0	128,492	64.6%
2025-07-29	41,527	0	133,286	31.2%
2025-07-28	44,820	1,104	199,290	22.5%
2025-07-25	38,438	6	75,237	51.1%
2025-07-24	72,747	28	125,300	58.1%
2025-07-23	27,864	0	77,643	35.9%
2025-07-22	50,068	0	117,137	42.7%
2025-07-21	63,682	7,051	239,269	26.6%
2025-07-18	39,727	258	109,464	36.3%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE